Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Health-related QoL in ipilimumab treated advanced melanoma survivors

Christian Blank • 27 Sep 2019
ESMO 2019
Melanoma Skin Cancer Checkpoint Inhibitors Ipilimumab

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Christian Blank

Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
1:55
Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank • 16 Apr 2021
The future of adjuvant therapy in melanoma
1:44
The future of adjuvant therapy in melanoma
Christian Blank • 19 Apr 2021
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
1:16
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank • 19 Apr 2021
Predicting resistance to targeted therapies in melanoma
1:09
Predicting resistance to targeted therapies in melanoma
Christian Blank • 27 Sep 2019

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals